Defence Therapeutics CEO outlines three strategic priorities in letter

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. MRK
7. LVS
8. SAP
9. CSX
10. LRCX

Go back to Defence Therapeutics CEO outlines three strategic priorities in letter

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

September 8, 2026 3:17 AM EDT

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc.(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.

Dear Shareholders,

Defence Therapeutics is entering an exciting new stage in... More